← All trials
NCT04713956
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 15, 2021
- Primary completion
- Jul 31, 2023
- Completion date
- Jul 31, 2024
- First posted
- Jan 19, 2021
- Last posted
- Jan 19, 2021
- Enrollment
- 242
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Southern Medical UniversityLead sponsor
- Peking UniversityCollaborator
- Hacettepe UniversityCollaborator
- Southern Medical UniversityReponsible party - principal investigator
- Southern Medical UniversityOverall official - principal investigator
- Guangzhou Medical UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Chinese Academy of Medical SciencesCollaborator
- First People's Hospital of ChenzhouCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.